

# CONTENTS

*List of tables*

*List of figures*

*Abbreviations*

*Abstract*

---

<b>Chapters</b>	<b>Page No.</b>
<b>1 Introduction.....</b>	<b>1</b>
1.1 Breast cancer.....	1
1.1.1 Signs and symptoms of breast cancer.....	1
1.1.2 Cause and risk factors.....	1
1.1.3 Breast cancer treatment .....	3
1.1.4 Mechanism of receptor overexpression in breast cancer .....	5
1.1.5 Hormonal receptors over-expressed in breast cancer .....	5
1.1.6 Estrogen receptor (ER) .....	6
1.1.7 Progesterone receptor (PR).....	8
1.1.8 Androgen receptors.....	10
<b>2 Literature review .....</b>	<b>13</b>
2.1 Nanotherapy for cancer treatment.....	13
2.2 Nanomedicine for targeting overexpressed hormonal receptors.....	14
2.2.1 Liposomes.....	15
2.2.2 Polymeric Micelles.....	18
2.2.3 Solid lipid nanoparticles .....	21
2.2.4 Gold Nanoparticles.....	24
2.2.5 Polymeric nanoparticles .....	25
2.3 Theranostic nanomedicine for imaging and therapy of hormonal receptor positive breast cancer.....	28
2.4 Palbociclib for breast cancer therapy .....	32
2.4.1 Mechanism of action for Palbociclib in breast cancer therapy .....	32

---

<b>3</b>	<b>Chitosan-g-estrone nanoparticles of palbociclib for hypoxic breast tumor therapy</b>	<b>35</b>
3.1	Objective of the study.....	35
3.2	Plan of study.....	35
3.3	Materials.....	36
3.4	Methods.....	36
3.4.1	Synthesis of chitosan-g-estrone (CS-g-Egen) conjugate.....	36
3.4.2	Preparation of NPs.....	38
3.4.3	Characterization of nanoparticles.....	39
3.4.4	<i>In vitro</i> studies.....	42
3.4.5	<i>In vivo</i> studies.....	46
3.4.6	Statistical analysis.....	50
3.5	Results and discussion.....	50
3.5.1	Characterization of CS-g-Egen conjugate.....	50
3.5.2	Nanoparticles characterization.....	55
3.5.3	Surface chemistry by XPS.....	59
3.5.4	<i>In vitro</i> studies.....	61
3.5.5	Pharmacokinetic study.....	71
3.5.6	Histopathology study.....	73
3.5.7	<i>In vivo</i> antitumor activity by ultrasound/photoacoustic imaging.....	73
3.5.8	<i>In vivo</i> breast tumor targeting efficiency by IVIS live imaging.....	79
3.6	Conclusion.....	80
<b>4</b>	<b>Theranostic chitosan nanoparticles for the co-delivery of PLB and UMN.....</b>	<b>83</b>
4.1	Objective of the study.....	83
4.2	Plan of the study.....	83
4.3	Materials.....	84
4.4	Methods.....	84
4.4.1	Preparation of UMN.....	84
4.4.2	Formulation of theranostic NPs.....	85
4.4.3	Characterization of nanoparticles.....	86

4.4.4	<i>In vitro</i> studies .....	90
4.4.5	<i>In vivo</i> studies .....	93
4.4.6	Statistical analysis.....	97
4.5	Results and discussion .....	97
4.5.1	Characterization of UMN .....	97
4.5.2	Nanoparticles characterization.....	98
4.5.3	<i>In vitro</i> studies .....	103
4.5.3.4	<i>In vitro</i> cellular uptake study .....	106
4.5.4	Pharmacokinetic study.....	111
4.5.5	Histopathology Study .....	113
4.5.6	<i>In vivo</i> breast tumor imaging by USG/PA.....	114
4.5.7	<i>In vivo</i> fluorescent imaging of the breast tumor .....	123
4.6	Conclusion .....	124
<b>5</b>	<b>Summary and future prospects .....</b>	<b>127</b>
<b>6</b>	<b>References.....</b>	<b>129</b>
<b>7</b>	<b>Publications from the research work .....</b>	<b>147</b>
<b>8</b>	<b>Curriculum Vitae.....</b>	<b>155</b>



## **Abbreviations and Symbols**

%	Percentage
°	Degree
µg	Microgram
µl	Microliter
AFM	Atomic force microscope
ALT	Alanine aminotransferase
ANP	1-amino 4-nitro naphthalene
AST	Aspartate aminotransferase
CS	Chitosan
CM6	Coumarin-6
CI	Combination index
CLSM	Confocal laser scanning microscope
cm	Centimeter
DAPI	4',6-diamidino-2-phenylindole
DMAB	Di-dodecyldimethyl ammonium bromide
DMBA	7, 12-dimethylbenz [α] anthracene
DMEM	Dulbecco's modified Eagle's medium
DPPH	1,1-diphenyl-2-picrylhydrazyl
DRI	Dose reduction index
DSC	Differential scanning calorimetry
EDTA	Ethylenediaminetetraacetic acid
EE	Entrapment efficiency
Egen	Estrone
FA	Folic acid
FBS	Fetal bovine serum
GRAS	Generally regarded as safe
GSH	Glutathione
h	Hour
USG	Ultrasound
HPLC	High performance liquid chromatography
PA	Photoacoustic
IS	Internal standard
kD	Kilodalton
kg	Kilogram
l	Liter
LLOQ	Lower limit of quantification
LOD	Limit of detection

LOQ	Limit of quantification
UMN	Ultrasmall magnesium nanocluster
MEM	Minimum essential medium
mg	Milligram
min	Minute
ml	Milliliter
MTS	(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
MTT	(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
NPs	Nanoparticles
ng	Nanogram
nm	Nanometer
NMR	Nuclear magnetic resonance
PDI	Polydispersity index
PI	Propidium iodide
RSD	Relative standard deviation
RSM	Response surface methodology
SD	Standard deviation
sec	Second
SEM	Scanning electron microscope
Sem	Standard error of mean
PS	Particle size
PDI	Polydispersity Index
PLB	Palbociclib
TEM	Transmission electron microscope
TOS	Total solid content
w/v	Weight-by-volume
w/w	Weight-by-weight
XRD	X-ray diffraction
XPS	X-ray photoelectron spectroscopy
ZP	Zeta Potential
$\theta$	Theta

# List of Tables

---

<b>Table No.</b>	<b>Description</b>	<b>Page No.</b>
Table 1.1.	Various drugs/biological agents for the treatment of breast cancer .....	4
Table 2.1	Drug profile of Palbociclib (PLB).....	33
Table 3.1	Composition of the various NPs formulations .....	39
Table 3.2	FTIR peak assignment of CS, Egen, Egen-COOH, and CS-g-Egen .....	51
Table 3.3	PS, PDI, ZP, EE and IC <sub>50</sub> value of developed NPs .....	56
Table 3.4	Pharmacokinetic parameters of PLB, non-targeted NPs (PLB-CS-g-Egen NPs) and targeted NPs (PLB-CS-g-Egen NPs) after i.v injection at an equivalent PLB dose of 5.91 mg/kg. ....	73
Table 4.1	The formulation composition of the FR targeted, nontargeted, ER targeted, and dual receptor targeted theranostic NPs .....	86
Table 4.2.	Particle size, polydispersity, zeta potential, entrapment efficiency, and IC <sub>50</sub> value of developed NPs. ....	99
Table 4.3	Pharmacokinetic parameters of PLB, nontargeted NPs, folate receptor targeted NPs, estrogen receptor targeted NPs and dual receptor targeted NPs after <i>i.v</i> injection at an equivalent PLB dose of 5.91 mg/kg.....	112

---



# *List of Figures*

---

<b>Figure No.</b>	<b>Description</b>	<b>Page No.</b>
Figure 2.1	Schematic representation of various nanomedicines: (A) Polymeric nanoparticles (B) Core-shell polymeric nanoparticles (C) Liposomes (D) Micelles (E) Nanofibers (F) Nanovesicles (G) Stimuli-response supramolecular nanomedicine (H) Host-guest nanocomplex .....	19
Figure 2.2	Schematic drawing of polymeric solid lipid NPs for imaging and therapy of tumor. ..	23
Figure 2.3.	Schematic representation of the targeted polymeric NPs for PLB delivery to breast cancer cells.....	28
Figure 2.4.	Targeted theranostic NPs for targeted breast cancer imaging and therapy .....	31
Figure 3.1.	Method of preparation of chitosan NPs by solvent evaporation/ionic crosslinking.....	39
Figure 3.2	FTIR-ART spectra of the chitosan, Egen, Egen-COOH and CS-g-Egen .....	51
Figure 3.3	NMR spectra of A) CS, B) Egen, C) Egen-COOH and D) CS-g-Egen .....	53
Figure 3.4	HRMS spectra of A) Egen-COOH showing M+H peak of Egen and Egen-COOH, A.1) showing M+H peak of Egen, A.2) showing M+H & M+2H peak of Egen-COOH B) CS-g-Egen.....	54
Figure 3.5	Statistical comparison of PLB, PLB-CS NPs, and PLB-CS-g-Egen NPs (A) particle size and (B) zeta potential. ....	56
Figure 3.6	Morphological imaging of the PLB-CS NPs and PLB-CS-g-Egen NPs by (A) field emission scanning electron microscope (FE-SEM), (B) transmission electron microscope (TEM).....	58
Figure 3.7	(A) two dimensional atomic force microscope (AFM) and (B) three-dimensional AFM. ....	59

---

Figure 3.8 A) X-ray photoelectron spectroscopy (XPS) analysis of PLB-CS NPs and PLB-CS-g-Egen NPs, B) X-ray diffraction (XRD) spectra of the PLB, CS, Egen, Egen-COOH, CS-g-Egen, PLB-CS NPs and PLB-CS-g-Egen NPs.....	60
Figure 3.9 <i>In vitro</i> drug release profile of the PLB and NPs formulations in the pH 5.5 acetate buffer and pH 7.4 phosphate buffer saline. ....	62
Figure 3.10 Statistical comparison of PLB, PLB-CS NPs, and PLB-CS-g-Egen NPs (A) T <sub>50</sub> at pH 5.5 and (B) T <sub>50</sub> at pH 7.4. ....	62
Figure 3.11 (A & B) Hemolysis study; I) Distilled water, II) Saline, III) PLB, IV) PLB-CS NPs, V) PLB-CS-g-Egen NPs and (C) hemocompatibility study; I) Distill water, II) Saline, III) PLB, IV) PLB-CS NPs, V) PLB-CS-g-Egen NPs.....	65
Figure 3.12 Confocal laser scanning microscopy (CLSM) images demonstrating cellular uptake of the free CM6 (first row), CM6-CS NPs (second row), CM6-CS-g-Egen NPs (third row), and CM6-CS-g-Egen NPs after pretreatment with Egen (fourth row) in (A) MCF-7 cells and (B) T-47D cells. The left column (CM6 channel) shows green fluorescence of CM6 distributed in the cytoplasm of (A) MCF-7 cells & (B) T-47D cells, the middle column (PI channel) shows red fluorescence from PI stained nucleus and the right column (merged) shows the CM6, CM6 loaded NPs, and PI stained nucleus. % Mean fluorescent intensity (green channel) in (C) MCF-7 cells and (D) T-47D cells after cellular uptake of CM6, CM6-CS NPs and CM6-CS-g-Egen NPs. ....	67
Figure 3.13 Cellular cytotoxicity assessment of the PLB, PLB-CS NPs and PLB-CS-g-Egen NPs on MCF-7 cells (A & B) and T-47D cells (C & D).....	68
Figure 3.14 Apoptosis study of PLB, PLB-CS NPs, and PLB-CS-g-Egen NPs in (A) MCF-7 cells and (B) T-47D cells. ....	69
Figure 3.15 Cell cycle distribution analysis of MCF-7 cells after treatment with A) free PLB, B) PLB-CS NPs, and PLB-CS-g-Egen NPs. D) statistical comparison of cell cycle distribution analysis of Free PLB, PLB-CS NPs, and PLB-CS-g-Egen NPs. ....	71
Figure 3.16 (A) Pharmacokinetic study showing plasma concentration vs time profile of drug concentration after intravenous administration of PLB, PLB-CS-g-Egen NPs and PLB-	

CS-g-Egen NPs, (B) Histopathological images of the rats vital organs after treatments with PLB. The arrow (red) indicates the location of the lesions.....	72
Figure 3.17 (A) Ultrasound and Photoacoustic imaging of the breast tumor before and after treatment with PLB, PLB-CS NPs, and PLB-CS-Egen NPs, (B) Effect of the treatments on the tumor size in rats with PLB, PLB-CS NPs and PLB-CS-Egen NPs. ....	74
Figure 3.18 (A) Ultrasound and photoacoustic images of the breast tumor before and after treatment with PLB, PLB-CS NPs and PLB-CS-Egen NPs and (B) analysis of the hypoxic tumor volume. ....	76
Figure 3.19 (A) Power Doppler images of the breast tumor before and after treatment with PLB, PLB-CS NPs and PLB-CS-Egen NPs and (B) analysis of angiogenesis and tumor vascularity.....	77
Figure 3.20 A) Histopathological H & E staining of normal, saline treated, PLB treated, PLB-CS NPs treated and PLB-CS-g-Egen NPs treated rat breast tumor sample. B) B&W images of separated nuclei of normal, saline treated, PLB treated, PLB-CS NPs treated and PLB-CS-g-Egen NPs treated rat breast tumor sample, C) histogram showing a number of separated nuclei from H & E and presented in B&W images. ....	78
Figure 3.21. Kaplan-Meier survival analysis plot. Healthy rats and PLB- CS-g-Egen NPs treated rats had 100 % survival (back and violet lines superimposed). ....	79
Figure 3.22. A) <i>In vivo</i> biodistribution in DMBA induced breast cancer model, and (B) Control rat imaging without DiD administration. C) Histogram showing radiant efficiency at different time intervals.....	80
Figure 4.1 A) Fluorescent images of UMN at day light, Ex 366 nm (blue) and Ex 469 nm (green), B) TEM image of UMN, C) and D) UMN excitation and emission spectra.....	98
Figure 4.2 Microscopic images of PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs, and PLB-UMN-CS-FA-ES-NPs by (A) FE-SEM, (B) TEM, (C) 2D AFM) and (D) 3D AFM. ....	100
Figure 4.3 A) XPS analysis of PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs by XPS, B) XRD graph of PLB, CS, ES, FA,	

UMN, CS-ES, CS-FA, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs. <i>In vitro</i> PLB release at C) pH 4.5, D) pH 6.5, and E) pH 7.4 from nanoformulations.....	102
Figure 4.4 (A) Hemocompatibility study; I) DI water, II) Saline, III) UMN, IV) PLB, V) PLB-UMN-CS-NPs, VI) PLB-UMN-CS-FA-NPs, VII) PLB-UMN-CS-ES-NPs and VIII) PLB-UMN-CS-FA-ES-NPs, (B) Hemolysis study; DI water, Saline, UMN, PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs,.....	105
Figure 4.5 <i>In vitro</i> physiological stability of the NPs in plasma and serum. ....	106
Figure 4.6 Cellular uptake of the free UMN, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs, PLB-UMN-CS-FA-ES-NPs and after pretreatment with FA+ ES in (A) MCF-7 cells and (B) T-47D cells. % Mean fluorescent intensity per cell in (C) MCF-7 cells and (D) T-47D cell following cellular internalization of PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs. ....	108
Figure 4.7 Cellular cytotoxicity assessment of the PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs, and PLB-UMN-CS-FA-ES-NPs on MCF-7 cells (A & B) and T-47D cells (C & D). ....	110
Figure 4.8 Cell cycle study of MCF-7 cells following incubation with A) free PLB, B) PLB-UMN-CS-NPs, C) PLB-UMN-CS-FA-NPs, D) PLB-UMN-CS-ES-NPs and E) PLB-UMN-CS-FA-ES-NPs, F) Graphical presentation of cell cycle study of free PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-FA-ES-NPs. ....	111
Figure 4.9 Pharmacokinetic study of PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs following <i>i.v.</i> injection. ....	113
Figure 4.10. H & E stained images following administration with PLB, PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs. The arrow in black color indicated lesion/damage to vital organs. ....	114

Figure 4.11 (A) *In vivo* breast tumor imaging of the rat by USG and PA imaging before and after treatment with PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs, (B) Comparison of breast tumor size reduction among control, PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs, and PLB-UMN-CS-FA-ES-NPs treated groups..... 115

Figure 4.12 (A) Hypoxic breast tumor volume estimation in rats by USG and PA imaging following administration with PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs and (B) Statistical comparison of the hypoxic tumor volume among different treatment groups..... 117

Figure 4.13 (A) Breast tumor images showing tumor vascularity following treatment with PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs and (B) Statistical comparison of tumor vascularity among different treatment group. .... 120

Figure 4.14 A) Histopathological H & E staining of normal, saline treated, PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs treated rat breast tumor samples. B) B&W images of separated nuclei of normal, saline treated, PLB, PLB-UMN-CS-NPs..... 121

Figure 4.15 Kaplan-Meier survival analysis plot of healthy rats (without tumor), control (rats with tumor, saline treated), PLB, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs, and PLB-UMN-CS-FA-ES-NPs. Healthy rats and PLB-UMN-CS-FA-ES-NPs treated rats had 100 % survival (black and green lines superimposed)..... 122

Figure 4.16. Targeted delivery of PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs, A) *In vivo* biodistribution of UMN, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs at 0.5, 2, 4 and 6 h after intravenous administration on DMBA induced breast cancer model. B) Histogram showing radiant efficiency of UMN, PLB-UMN-CS-NPs, PLB-UMN-CS-FA-NPs, PLB-UMN-CS-ES-NPs and PLB-UMN-CS-FA-ES-NPs after administration at different time intervals. The breast tumor has been circled (in red) on the left (first,

second, third and fifth row) or right (fourth row) side of the breast. ns ( $P \geq 0.05$ ), \* ( $P < 0.05$ ), \*\* ( $P < 0.01$ ), \*\*\* ( $P < 0.001$ ), and \*\*\*\* ( $P < 0.0001$ )..... 124